PCCS: Coenzyme Q10 Improves Cardiac Function in Children with Dilated Cardiomyopathy
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




PCCS: Coenzyme Q10 Improves Cardiac Function in Children with Dilated Cardiomyopathy

By Cameron Johnston
Special to DG News

TORONTO, ON -- May 30, 2001 -- An enhanced formulation of a popular weight loss product found in health food stores, coenzyme Q10, may be useful in helping to improve heart function in young people with dilated cardiomyopathy.

In a small study presented here today at the 3rd World Congress on Pediatric Cardiology and Cardiac Surgery, Drs. Elshershari and Ozer from the Haceteppe University Faculty of Medicine in Ankara, Turkey, reported that Q10 proved to be "remarkably beneficial" when used to treat three children with dilated cardiomyopathy.

Q10 is a micro-nutrient which provides nourishment for the cellular mitochondria. It is well-known that cardiac metabolism is directly associated with this mitochondrial respiratory chain, and that up to 25 percent of all cardiomyopathies are associated with mitochondrial disease.

The children in the study ranged in age from four to 12 months and had NYHA (New York Heart Association) class III heart disease. The patients were given coenzyme Q10 mixed with soya oil, 10 mg/day, B.I.D., and were followed for a mean of six months. The Q10 was delivered as an adjunct to their standard therapy, which consisted of an ACE inhibitor, diuretics and digoxin.

As a result of using coenzyme Q10, the patients’ heart disease classification decreased from NYHA III to NYHA I. They also experienced a significant change in fractional shortening which is a measure of ventricular function, and a significant increase in
left ventricular ejection fraction. Chest X-ray revealed a decrease in cardio-thoracic ratio. Electrocardiogram also revealed a regression of left ventricular hypertrophy and a complete disappearance of left ventricular strain.

The patients went through an initial monitoring period of one to eight months during which they received only standard therapy. During this phase of the study, there were no meaningful changes in any measured parameters - all of the change occurred when Q10 was added, Dr. Elshershari said.

Despite the fact that Q10 does not have any effect on left ventricular function in adults, it was beneficial for these young patients, she said. A possible weakness in the study is that plasma Q10 levels were not measured at baseline, nor were endomyocardial biopsies performed.

At least part of the motivation for this study was that results of biopsies of hearts suffering from dilated cardiomyopathy found them to be deficient in Q10, Dr. Elshershari explained.

"Because of the small size of this study, we can’t definitely say this was the answer, or recommend its use for all cases of cardiomyopathy," she said. Nonetheless, it is worth pursuing in a further study to determine the true benefit of this product in treating children with idiopathic dilated cardiomyopathy.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities